/Cardinal%20Health%2C%20Inc_%20logo%20on%20building%20by-%20JHVEPhoto%20via%20Shutterstock.jpg)
Cardinal Health, Inc. (CAH) is a leading global healthcare services and products company headquartered in Dublin, Ohio. With a market cap of $35.5 billion, it serves over 100,000 locations worldwide, including hospitals, pharmacies, and laboratories.
CAH stock has soared 51.2% over the past 52 weeks and is up 25.4% in 2025, outpacing the S&P 500 Index’s ($SPX) 12.7% gains over the past year and a marginal surge on a YTD basis.
Zooming in further, CAH has also surpassed the SPDR S&P Health Care Services ETF’s (XHS) 8.2% gains over the past year and 8.8% rise in 2025.
Cardinal Health surged to a record high on May 1, closing 3% higher, after reporting strong fiscal Q3 earnings and raising its full-year EPS guidance to $8.05–$8.16, surpassing the consensus estimate of $7.96. The company remains in a long-term 3-year uptrend, bolstered by steady performance in both its Pharmaceutical and Medical segments. It posted an adjusted profit of $2.35 per share, surpassing Wall Street's expectations of $2.15 per share. However, its revenue of $54.88 billion fell short of the forecasted $55.03 billion.
For the current year ending in June, analysts expect Cardinal’s earnings to grow 7.8% year-over-year to $8.12 per share. Furthermore, the company has a robust earnings surprise history. It surpassed the Street’s bottom-line expectations in each of the past four quarters.
Among the 15 analysts covering the CAH stock, the consensus rating is a “Strong Buy.” That’s based on 11 “Strong Buy” and four “Hold” ratings.
This configuration has remained consistent over the past months.
On May 5, Morgan Stanley (MS) raised its price target on Cardinal Health from $142 to $166, while maintaining an “Overweight” rating. The firm cites steady utilization supporting Core Pharma growth and believes Cardinal has potential for further re-rating, with the analyst highlighting the current period as a "Golden Era" for drug distribution.
CAH’s mean price target of $154.88 suggests a 4.5% premium to current price levels, while its street-high target of $173 indicates a 16.7% upside potential.
